G1 THERAPEUTICS IN

NASDAQ

GTHX

Earnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented so far...

paints quite a different picture. The ABC is not quite complete yet. There is a potential drop from $21 to $12.

@emarler this one fit the CODE

@emarler

this one is very interesting

GTHX: g1 therapeutics inc 2018-03-05 06:00:22 Detected possible positive results in drug trial